Please use this identifier to cite or link to this item:
|Title:||Putting Pharmacogenetics into Practice|
|Authors:||HOPKINS Michael; IBARRETA RUIZ DOLORES; GAISSER Sibylle; ENZING Christien E.; RYAN Jim; MARTIN Paul A.; LEWIS Graham; DETMAR Symone; VAN DEN AKKER-VAN MARLE Elske; HEDGECOE Adam M.; NIGHTINGALE Paul; DREILING Marieke; HARTIG K. Juliane; VULLINGS Wieneke; FORDE Tony|
|Citation:||NATURE BIOTECHNOLOGY vol. 24 no. 4 p. 403-410|
|Publisher:||NATURE PUBLISHING GROUP|
|Type:||Articles in Journals|
|Abstract:||Pharmacogenetics has been suggested as the area of genetics with the most potential to rapidly provide public health benefits . While early expectations of ‘tailor-made’ or ‘personalised’ medicines may have been over-hyped or even misleading and remain mostly unfulfilled, more modest benefits are still widely anticipated [2-4]. Here we assess progress in exploiting pharmacogenetics and current challenges for those attempting to put it into practice. This study is based on a comprehensive review of the industry and the science base in the USA, Europe and Japan as well as the institutional support frameworks needed for the development and use of genetic predictors of drug response in the EU and USA. The findings derive from a recently completed European Science and Technology Observatory (ESTO) study. The study used diverse methods including a range of publication and commercial database search strategies, online-surveys and in-depth interviews as the basis for its analysis.|
|JRC Institute:||Institute for Prospective Technological Studies|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.